Meloxicam Ciclum

Meloxicam, the active ingredient in Meloxicam Ciclum, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for systemic use. It is used to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute musculoskeletal pain in adult patients.

GNH USA supplies Meloxicam Ciclum as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global distribution. Our supply chain adheres to stringent standards to ensure product integrity throughout transit.

Meloxicam is an NSAID that reduces inflammation and pain in several musculoskeletal and rheumatic conditions.

- Osteoarthritis: reduces joint pain and improves function in patients with degenerative joint disease. - Rheumatoid arthritis: alleviates inflammatory joint pain and swelling in chronic autoimmune arthritis. - Ankylosing spondylitis: diminishes spinal pain and stiffness associated with inflammatory axial spondyloarthritis. - Acute pain: provides rapid relief of short‑term musculoskeletal pain such as sprains or post‑procedural discomfort.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Diarrhea: loose stools occurring intermittently. - Headache: mild to moderate tension‑type pain. - Dizziness: transient light‑headedness. - Hypertension: modest increase in blood pressure. - Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding: potentially life‑threatening hemorrhage. - Cardiovascular events: myocardial infarction or stroke, especially with long‑term use. - Hepatic injury: elevated liver enzymes or hepatitis. - Renal impairment: acute kidney injury or worsening chronic kidney disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: rare but potentially fatal hypersensitivity reaction.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Assess gastrointestinal risk: review history of ulcers, bleeding, or chronic NSAID use. - Evaluate cardiovascular profile: consider existing heart disease or hypertension. - Monitor renal function: check serum creatinine and electrolytes in patients with kidney disease. - Check hepatic status: perform baseline liver function tests in patients with liver impairment. - Use lowest effective dose: limit duration to the shortest period necessary for symptom control. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture and direct sunlight.

Meloxicam may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: elevated lithium levels leading to toxicity. - Methotrexate: reduced clearance and potential toxicity. - High‑dose aspirin: enhanced renal and gastrointestinal adverse effects.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: heightened risk of renal impairment and electrolyte imbalance. - SSRIs or SNRIs: increased bleeding tendency. - Beta‑blockers: potential attenuation of antihypertensive effect. - Corticosteroids: synergistic gastrointestinal ulcer risk.